Acrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing To Advance Its Innovative Precision Proteomics Platform And Clinical Oncology Pipeline
Amount Raised
$100 Million
Round Type
Series B
WatertownBiotechnologyHealth CareMedicalTherapeuticsBiopharmaDescription
Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based medicine, today announced the successful completion of an oversubscribed $100 million Series B financing. The financing was co-led by Wellington Management Company and Surveyor Capital (a Citadel company), with key participation from RA Capital Management and Perceptive Advisors. Additional new investors in the financing included Sands Capital, HBM Healthcare Investments, Marshall Wace, HealthCor Management, BB Pureos Bioventures, Acorn Bioventures, and existing investors, including Alexandria Venture Investments and Chione Ltd. In connection with the financing, Derek DiRocco, Ph.D., partner at RA Capital Management, will join the company’s Board of Directors.
Quick answer
Acrivon Therapeutics raised $100 Million in a Series B round, dated November 11, 2021. Acrivon Therapeutics is based in Watertown, Massachusetts, United States.
- How much did Acrivon Therapeutics raise?
- Acrivon Therapeutics raised $100 Million in a Series B round on November 11, 2021.
- What does Acrivon Therapeutics do?
- Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform.
- Where is Acrivon Therapeutics based and how big is it?
- Acrivon Therapeutics is based in Watertown, Massachusetts, United States. Fundz records about 11 employees.
- Who are the decision-makers at Acrivon Therapeutics?
- Fundz holds 3 contacts at Acrivon Therapeutics, including the Chief Legal Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Medical and Therapeutics around the same time
Companies in the same sectors as Acrivon Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Arcutis raised $225M (Debt Financing) on December 23, 2021.
- AnHeart Therapeutics raised $61M (Series B) on December 14, 2021.
- AEON Biopharma raised $30M on December 8, 2021.
- Compugen raised $20M on November 22, 2021.
- Xencor raised $25M on November 19, 2021.
- Chase Therapeutics Corporation raised $20M (Series B) on October 20, 2021.
Who to call at Acrivon Therapeutics, and when
A new round usually means Acrivon Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Acrivon Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Acrivon Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Acrivon Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Acrivon Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAcrivon Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.